Longshen Rongfa Co., Ltd.

Announcement on the Implementation of the 2025 Annual Dividend Distribution

Announcement on Receiving the Gansu Securities Regulatory Bureau's Order for Correction and Warning Letter, and Regulatory Talks with Responsible Personnel

Announcement on the Completion of Business Registration Change and Reissuance of Business License by the Controlling Subsidiary

Financial Statements and Related Notes After Correction of Prior Period Accounting Errors

Announcement on Correction of Prior Period Accounting Errors

Verification Opinion from Hualong Securities Co., Ltd. on the Impairment Test of Assets Upon Expiration of Performance Commitment Period for Gansu Longshen Rongfa Pharmaceutical Co., Ltd.

Review Report on the Impairment Test of Target Assets Upon Expiration of Performance Commitment Period for Gansu Longshen Rongfa Pharmaceutical Co., Ltd.

Announcement on the Impairment Test of Target Assets Upon Expiration of Performance Commitment Period for Major Asset Restructuring

Resolution Announcement of the 28th Meeting of the 5th Board of Directors

Q1 2026 Report

Legal Opinion for the Annual Shareholders' Meeting for the Year 2025

Announcement of Resolutions from the Annual Shareholders' Meeting for the Year 2025

Announcement on the Change of Disclosure Time for the First Quarter Report of 2026

Announcement on Holding the Online Performance Briefing for the Year 2025

Special Explanation on the Retrospective Adjustment of Previous Financial Statements for Gansu Longshen Rongfa Pharmaceutical Co., Ltd. in 2025 Due to Mergers Under Common Control

2025 Annual Board Work Report

Reminder Announcement on the Disclosure of the 2025 Annual Report

Announcement on Retrospective Adjustment of Financial Data for Mergers Under Common Control

Independent Director Work Report for the Year 2025 (Luo Zhen)

Independent Director Work Report for the Year 2025 (Wu Ye)

Independent Director Work Report for the Year 2025 (Li Zongyi, Resigned)

Independent Director Work Report for the Year 2025 (Fang Wenbin)

Internal Control Audit Report for the Year 2025

Internal Control Evaluation Report for the Year 2025

Future Shareholder Return Plan (2026-2028)

Internal Accountability System for Directors and Senior Management (April 2026)

Compensation Management System for Directors and Senior Management (April 2026)

Announcement on the Estimated Daily Related Transactions for the Year 2026

Notice on Convening the 2025 Annual Shareholders' Meeting

Announcement of the Resolution of the Twenty-Seventh Meeting of the Fifth Board

Announcement on the Profit Distribution Plan for the Year 2025

Verification Opinion by Hualong Securities Co., Ltd. on the Achievement of Performance Commitment for the Major Asset Purchase and Related Transactions of Gansu Longshen Rongfa Pharmaceutical Co., Ltd. for the Year 2025

Special Review Opinion on the Achievement of Performance Commitment by Gansu Puan Pharmaceutical Co., Ltd.

Special Explanation on the Completion of Performance Commitment by Gansu Puan Pharmaceutical Co., Ltd. for the Year 2025

Evaluation Report on the Performance of the Accounting Firm for the Year 2025

Report of the Board Audit Committee on the Performance of Supervisory Responsibilities by the Accounting Firm for the Year 2025

Special Explanation on the Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions of Gansu Longshen Rongfa Pharmaceutical Co., Ltd.

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Special Opinion of the Board on the Independence of Independent Directors

Audit Report for the Year 2025

Annual Report for the Year 2025

Summary of the Annual Report for the Year 2025

Announcement on Obtaining the Renewed 'Drug Production License'

Related Party Transaction Announcement

Resolutions Announcement of the Twenty-Sixth Meeting of the Fifth Board of Directors

Announcement on the Completion of Industrial and Commercial Change Registration and Issuance of New Business License by a Holding Subsidiary